Multiple Sclerosis Discovery Forum

Inspiring Connections

Most Viewed

Dispositional optimism is unidimensional or bidimensional? The Portuguese revised Life Orientation Test.
Inhibition of Neuronal Degenerin/Epithelial Na+ Channels by the Multiple Sclerosis Drug 4-Aminopyridine.
The effects of intrathecal rituximab on biomarkers in multiple sclerosis.
A biopsychosocial model of resilience for multiple sclerosis.
Recurrent disease-activity rebound in a patient with multiple sclerosis after natalizumab discontinuations for pregnancy planning.
Low-contrast visual tests reveal better alemtuzumab efficacy
Benign Multiple Sclerosis: Does it exist?
"Tell me what you want, what you really really want….": asking people with multiple sclerosis about enhancing their participation in physical activity.
Recombinant T-Cell Receptor Ligand (RTL) for Treatment of Multiple Sclerosis: A Double-Blind, Placebo-Controlled, Phase 1, Dose-Escalation Study.
Efficacy of Cyclophosphamide Versus Methylprednisolone in Patients With Secondary Progressive Multiple Sclerosis (PROMESS)
Transcriptomics: mRNA and alternative splicing.
Isolated trigeminal nerve palsy with motor involvement as a presenting manifestation of multiple sclerosis in an equatorial region - a case report.
Genmab collaborator GSK starts new ofatumumab Phase III study in rare skin disorder
Mu opioid receptor activation modulates Toll like receptor 4 in murine macrophages.
Stabilization of rapidly worsening multiple sclerosis for 36 months in patients treated with interferon beta plus cyclophosphamide followed by interferon beta.
[Cyclophosphamide pulse therapy effective for childhood-onset refractory multiple sclerosis: a case report].
Human iPSC-derived oligodendrocyte progenitor cells can myelinate and rescue a mouse model of congenital hypomyelination.
B cells from glatiramer acetate-treated mice suppress experimental autoimmune encephalomyelitis.
Assessing the impact of multiple sclerosis disease activity and daclizumab HYP treatment on patient-reported outcomes: Results from the SELECT trial.
Synthon obtains approval for glatiramer acetate 20 mg/mL in Europe
Prolonged-release fampridine and walking and balance in MS: randomised controlled MOBILE trial.
CD46: The 'multitasker' of complement proteins.
Genzyme’s Lemtrada™ approved in Canada for treatment of multiple sclerosis
Microvesicles: novel biomarkers for neurological disorders.
Discovery of fingolimod, the sphingosine 1-phosphate receptor modulator and its application for the therapy of multiple sclerosis.

Pages